Orthobiologics Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (DBM, Allograft, BMP, Viscosupplementation), By Application (Spinal Fusion, Trauma Repair), By End Use, By Region, And Segment Forecasts

Demand Drivers

a. Sports Participation and Injuries

A significant driving force for the orthopedics industry is increasing participation in sports and related events, leading to a rising incidence of injuries. These often include hip, knee, and shoulder fractures, which subsequently increase the demand for orthopedic surgeries.

• According to the National Safety Council (U.S.), 3.7 million people sustained sports-related injuries in 2023.

Table 1 Estimated number of sports injuries in the U.S., 2023

Source: Secondary Research, National Safety Council

• Furthermore, Standard Children’s Health reports that approximately 3.5 million children and teens incur injuries annually, out of 30 million who participate in sports in the U.S.

• An article by the American Orthopaedic Foot & Ankle Society highlights that lower extremity injuries are the most common in sports, especially among children. Research conducted over 3 years in 27 U.S. high schools showed that the majority of these injuries occurred during soccer, indoor track races, and cross-country races.

b. Road Accidents

An increasing number of road accidents also contributes to orthopedic injuries, thereby boosting demand for treatment solutions like orthobiologics.

• As per the “Road Accidents in India-2022” report:

  • 461,312 road accidents were reported in 2022.

  • These caused 168,491 fatalities and 443,366 injuries.

  • Compared to the previous year, this represents:

    • 11.9% increase in accidents

    • 9.4% increase in fatalities

    • 15.3% increase in injuries

Patient Demographics and Health Trends

a. Aging Population

The rise in the aging population significantly increases susceptibility to orthopedic disorders. Such increasing orthopedic disorder cases among the senior population will foster market growth.

• According to a United Nations (UN) report:

  • The number of people aged 65 and above is expected to double over the next 30 years.

  • By 2050, the elderly population is projected to reach 1.6 billion, which will be over 16% of the global population.

    

• A recent NHIS survey shows that nearly 47.3% of U.S. adults aged 65 or older have been diagnosed with arthritis by a doctor.

b. Obesity Epidemic

Obesity is a significant contributor to orthopedic issues, including joint degeneration and arthritis.

• As per the 2022 World Obesity Atlas by the World Obesity Federation:

  • By 2030, 1 billion people globally will be living with obesity.

  • This includes 1 in 7 men and 1 in 5 women.

• According to NIHS data from 2019-2021:

  • Adults who are overweight or obese report higher rates of arthritis:

    • 15.5% of adults with healthy or underweight BMI reported being diagnosed with arthritis.

    • 20.5% of overweight adults reported arthritis.

    • 27.5% of obese adults reported arthritis.

In many OECD countries where weight data is self-reported, over half of adults are classified as overweight or obese, based on 2023 or the latest available figures. The U.S. had the highest obesity rate, with slightly more than one-third of adults identifying as obese. Chile and the UK also reported high rates, with just over 25% of adults affected. In contrast, South Korea reported the lowest obesity rate among the countries examined, at only 4.9%.

Treatment Advancements and Clinical Outcomes

Orthobiologics Patient Satisfaction

Increasing patient satisfaction with the orthobiologics procedure further is fueling the market growth.

• A study by Professor Mark Slevin, Professor of Cell Pathology at Manchester Metropolitan University, reveals:

  • Orthobiologic treatments have favorable outcomes in around 70% of patients.

  • These patients report less pain and increased mobility post-treatment.

Investment and Funding Trends

The market for orthobiologics is expected to grow due to increased investment in research and development and funding from leading medical device and biotechnology companies. In September 2021, Locate Bio, a company specializing in regenerative medicine and orthobiologics, raised USD 12.7 million in an equity investment round.

Funding Announcements

Orthopedic Funding By Year And Segment

• While total investment activity has declined slightly in the last two years, funding for later-stage companies has increased.

• Notably, disclosed investment amounts grew by 10% post-pandemic, focusing on long-term profitability.

  

Investment interest is strongest in:

• Spine

• Sports medicine

• Orthobiologics

  

b. Robotics and Digital Innovation in Orthopedics

• Medical Microinstruments, Inc. (MMI) raised USD 110 million in Series C financing to:

  • Expand the commercialization of the Symani Surgical System in emerging markets.

  • Support clinical trials and broaden application indications.

• The Symani technology replicates human hand movements at a microscopic scale and is applicable in:

  • Microsurgery and supermicrosurgery

  • Soft tissue and open surgical procedures

  • Including free flap reconstruction and trauma replantation

Market Concentration & Characteristics

Recent advancements in the field of orthobiologics have brought about a significant transformation in the way orthopedic conditions and injuries are treated. The use of bone graft substitutes, platelet-rich plasma (PRP) therapy, and stem cell treatments, among other innovative technologies, is leading to a revolution in orthobiologics. Advanced imaging techniques such as MRI and CT scans provide precise and accurate diagnosis and planning. With 3D printing, it is possible to create customized implants and scaffolds that are tailored to individual patients. Additionally, biotechnology and genetic engineering are opening new avenues to improve the regenerative potential of orthobiologics, which can lead to faster healing and better outcomes for patients.

The orthobiologics market is characterized by a high level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for DBM. In February 2023, Zimmer Biomet acquired Embody, an orthobiologics company primarily focusing on soft tissue healing for USD 155 million. The company’s portfolio includes the Tapestry RC implant, which is used for rotator cuff repair, and the Tapestry biointegrative implant that is used for tendon healing.

Orthobiologic products face strict regulatory requirements to ensure they meet high standards of quality, safety, and efficacy before entering the market. This safeguards the patient's health and fosters trust among healthcare professionals and consumers. Regulatory agencies, such as the Food and Drug Administration (FDA) in the U.S. and the European Medicines Agency (EMA) in Europe, establish guidelines and frameworks for the development, testing, and approval of orthobiologic therapies.

Traditional surgical procedures, while invasive, remain a feasible option for some patients who may not qualify for orthobiologics or those who prefer more established techniques. Additionally, pharmaceutical therapies, such as pain medications and anti-inflammatory drugs, provide non-invasive alternatives for managing symptoms associated with musculoskeletal disorders. Furthermore, medical devices, such as joint implants, provide long-lasting solutions for severe cases of joint degeneration.

Several players in the orthobiologics industry are expanding their business by entering new geographical regions to strengthen their market position and expand their product portfolio. Rising research and development activities create more opportunities for market players to enter new regions. In October 2023, Orthofix Medical Inc. received 510(k) clearance and fully launched OsteoCove, an advanced bioactive synthetic graft.

Product Insights

The viscosupplementation segment dominated the orthobiologics market in 2024 and accounted for the largest revenue share of 42.21%. Rising patient pool suffering from osteoarthritis and the increasing product launches are anticipated to boost market growth. According to a study titled " According to a recent study titled "Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050", the number of people diagnosed with osteoarthritis has increased by 132.2% since 1990, with around 595 million globally diagnosed with the condition in 2020. The study also predicts that by 2050, cases of osteoarthritis of the knee, hand, hip, and others is likely to increase by significant percentages of 74.9%, 48.6%, 78.6%, and 95.1%, respectively. Viscosupplementation using hyaluronic acid injections is commonly used to treat osteoarthritis due to its ease of use and good tolerance, thus contributing to market growth.

The stem cell therapy segment in the orthobiologics industry is anticipated to witness the fastest CAGR over the forecast period. The increasing global healthcare expenditure and a growing emphasis on personalized medicine have created a favorable environment for the expansion of the stem cell therapy market. Additionally, advancements in biotechnology and regenerative medicine have resulted in the development of innovative techniques and products within the stem cell therapy market.

Application Insights

The spinal fusion segment held the largest revenue share of over 48.29% in 2024. owing to the increasing prevalence of spine disorders worldwide. According to the ScienceDirect report, over 400,000 spinal fusion surgeries are performed in the U.S. annually. Moreover, consistent penetration of bone morphogenetic proteins, demineralized bone matrices, autografts, and allografts in spinal fusion surgeries, owing to their ability to provide high bone stability and rapid bone healing, is fostering segmental growth.

Furthermore, the increasing focus of key market players on the launch of novel products for bone healing is escalating market growth. In November  2023, OssDsign AB undertook a strategic shift to focus on the U.S. orthobiologics business. This change makes OssDsign AB a pure-play orthobiologics company. The company will concentrate its efforts on OssDsign Catalyst, a nanosynthetic bone graft product that can be easily scaled up and has high gross margins of 90% or more. OssDsign Catalyst is an off-the-shelf product that is used to stimulate healthy bone tissue formation in spinal fusion surgeries.

The reconstructive surgery segment is anticipated to register a significant CAGR over the forecast period. The growing demand for reconstructive surgeries due to an aging population and an increase in musculoskeletal disorders is fostering segment growth. According  to the ISAPS Global Survey, the number of procedures performed by plastic surgeons increased by 11.2% in 2022. A total of 18.8 million non-surgical and 14.9 million surgical procedures were performed worldwide, continuing the trend of a 41.3% increase over the last four years. Orthobiologics are a promising solution for enhancing bone healing, promoting soft tissue repair, and restoring joint function, driving their adoption in reconstructive procedures. 

End Use Insights

The hospitals segment dominated the orthobiologics industry in 2024 with a revenue share of over 75%. Hospitals play a crucial role in the utilization of orthobiologics due to their advanced medical infrastructure and comprehensive healthcare services. One of the primary factors driving the growth of orthobiologics in hospitals is the increasing demand for minimally invasive procedures. Orthobiologics provide an alternative to traditional surgical interventions by utilizing the body's natural healing processes. This reduces the need for extensive surgeries and lengthy hospital stays. Additionally, the integration of advanced imaging technologies and surgical techniques in hospitals makes it possible for orthopedic surgeons to administer orthobiologic agents with precision, thereby facilitating tissue regeneration and accelerating recovery.

The orthopedic clinics segment in the orthobiologics market is anticipated to register a significant growth rate over the forecast period due to the increasing trend towards ambulatory care and same-day surgeries. These facilities provide a convenient and cost-effective option for patients seeking minor orthopedic procedures or treatments for sports injuries. As per  the Definitive Healthcare report, Specialists One-Day Surgery Centers performed the highest number of knee replacement surgeries in 2022, accounting for 1.6% of the total knee replacement procedures.

Regional Insights

North America dominated the orthobiologics market in 2024 and accounted for the largest revenue share of 46.03%, owing to the technological advancements and a robust healthcare infrastructure. Furthermore, favorable reimbursement policies and supportive regulatory frameworks facilitate market growth. Moreover, the growing aging population in the region will escalate the market growth. For instance, the U.S. Census Bureau has released the Vintage 2022 Population Estimates, which show an increase of 0.2 years in the nation's median age from 2021 to 2022. Median age is the age at which 50% of the population is younger and the other 50% is older.

U.S. Orthobiologics Market Trends

The orthobiologics industry in the U.S. held the largest share of more than 75% in the North American region in 2024. The region's emphasis on technological innovation and research results in a continuous flow of improved orthobiologic products. In July  2021, Dr. Scott A. Rodeo from Hospital for Special Surgery was granted USD 50,000 from the Orthopaedic Research and Education Foundation to research an injectable biologic for knees.

Canada orthobiologics market is anticipated to register the fastest growth rate during the forecast period. Increasing government and private funding for the innovation of novel products is anticipated to boost market growth. In February 2023, ChitogenX Inc., a clinical-stage orthobiologics company, partnered with Polytechnique Montréal to secure a grant of USD 3,472,000 from The Natural Sciences and Engineering Research Council of Canada ("NSERC") and Prima Québec.

Europe Orthobiologics Market Trends

Europe orthobiologics industry is anticipated to register the fastest CAGR during the forecast period. With an aging population and rising life expectancy, the prevalence of age-related musculoskeletal conditions such as osteoarthritis fuels demand for orthobiologic interventions. Furthermore, the presence of various key market players in the region is boosting the market growth.

Germany orthobiologics market is anticipated to register a considerable growth rate during the forecast period. Growing participation of people in sports is expected to propel market growth. As per the deutschland.de report published in 2024, Germany has almost 90,000 sports clubs, which have approximately 28 million members.

The orthobiologics market in the UK is anticipated to register a considerable CAGR during the forecast period. Rising acceptance of orthobiologics as effective treatment options is driving market growth. Increasing joint replacement surgeries in the country are contributing to the rise in demand for orthobiologics. As per the NHS report, each year, over 70,000 knee replacements are performed in England and Wales, with the number increasing. The majority of total knee replacement patients are aged 65 or older.

Spain orthobiologics market is anticipated to register a significant growth rate during the forecast period. Increased prevalence of musculoskeletal disorders, such as osteoarthritis and fractures, is boosting market growth. According  to the International Osteoporosis Foundation, published in 2023, in Spain, a fragility fracture caused by osteoporosis takes place every two minutes, leading to a total of 330,000 fractures annually. The incidence of such fractures has been observed to be increasing due to the gradual aging of the population. It is predicted that the number of fragility fractures will rise by approximately 30% by 2034, resulting in 370,000 cases every year.

Asia Pacific Orthobiologics Market Trends

The Asia Pacific orthobiologics industry is expected to witness rapid growth due to a rising geriatric population, increasing healthcare expenditure, and growing awareness of minimally invasive orthopedic procedures. Countries such as Japan, India, South Korea, and Australia are leading the regional demand, driven by an increase in sports participation, traumatic injuries, and musculoskeletal disorders. Government initiatives to strengthen healthcare infrastructure and the growing presence of international orthopedic companies are also contributing to the region’s market expansion.

The China orthobiologics market represents a major growth hub in Asia Pacific due to its massive population base, growing elderly demographic, and rising incidence of orthopedic conditions such as osteoarthritis and spinal disorders. Robust R&D investments are also supporting the market, expanding private healthcare sectors, and national policies encouraging innovation in biotechnology and medical devices. Increased adoption of regenerative treatments and favorable regulatory reforms are further boosting the uptake of orthobiologics in the country.

Latin America Orthobiologics Market Trends

The Latin American orthobiologics industry is gradually expanding, driven by increasing awareness about regenerative therapies, a rising burden of orthopedic conditions, and an improving healthcare infrastructure in countries such as Mexico, Argentina, and Colombia. The growing trend toward sports and fitness activities, coupled with an aging population, is fueling demand for orthopedic interventions. However, challenges such as uneven access to advanced treatments and economic instability may hinder faster adoption in the region.

The Brazil orthobiologics market holds a dominant position in Latin America, due to its large population, strong public and private healthcare systems, and increasing incidence of trauma and sports-related injuries. The country has witnessed growing interest in regenerative medicine and advanced orthopedic treatments, supported by rising investments from both local manufacturers and international players. Regulatory developments and academic research collaborations are also paving the way for greater acceptance of orthobiologics in orthopedic surgeries.

Middle East & Africa Orthobiologics Market Trends

The orthobiologics industry in the Middle East and Africa is in a developing phase but shows promising potential. Increasing rates of road traffic accidents, a growing prevalence of obesity and osteoarthritis, and expanding access to private healthcare are driving market growth. Countries like the UAE, Saudi Arabia, and South Africa are investing in modern healthcare technologies, including regenerative orthopedic treatments. However, limited awareness and disparities in healthcare access across rural areas remain key challenges for widespread adoption.

Key Orthobiologics Company Insights

Key participants in the orthobiologics market are focusing on devising innovative business growth strategies in the form of product portfolio expansions, partnerships & collaborations, mergers & acquisitions, and business footprint expansions.

Some Initiatives By Key Stakeholders In The Orthopedic Industry

Orthopedic companies are launching a variety of products and services specifically designed for ambulatory surgical centers (ASCs):

• Johnson & Johnson Medical Device Companies has developed a platform to provide ASCs with diverse pricing and contracting options and operational support. This includes capital programs for purchasing/leasing equipment, rebates, coding/reimbursement assistance, and infection risk-management services.

• Stryker launched an ASC-focused business in 2020 that offers over 13,990 unique products across more than 22 procedure categories. Stryker provides flexible payment options for ASCs, including equipment leasing and customized payment plans.

Recent Developments

• In March 2025, Apollo Hospitals introduced a Joint Preservation Programme in India, aimed at early intervention and non-replacement treatment for joint issues. The initiative combines orthobiologic therapies, minimally invasive procedures, and personalized rehabilitation to extend joint life and delay the need for joint replacement surgeries.

• In September 2024, Temple OrthoBiologics officially launched with the goal of delivering next-generation sports medicine solutions, with a strong focus on women and youth. The company’s lead product, TX-33, is a protein-based biologic designed to support soft tissue repair and enhance recovery for active patients.

• In June 2024, Xtant Medical launched OsteoFactor PRO, a next-generation orthobiologic product designed to support bone healing and regeneration. The new solution expands Xtant’s portfolio in spine and orthopedic care, delivering a combination of demineralized bone matrix and bioactive growth factors.

• In September 2023, NuVasive, Inc. merged with Globus Medical, Inc. This merger aims to offer a wide range of musculoskeletal procedural solutions and enabling technologies to surgeons and patients.

• in February 2022, Orthofix Medical Inc. introduced Opus BA, a synthetic bone graft solution for lumbar and cervical spine fusion procedures. Opus BA is available in both strip and putty formulations and is designed to fill bone gaps or voids that are not part of the bony structure's stability in the skeletal system.

• .In August 2021, Seikagaku Corporation launched a new product named HyLink. It is a single injection viscosupplement designed for the treatment of knee osteoarthritis. The product has been launched in Taiwan and is being distributed through TCM Biotech International Corp., which is based in New Taipei City. 

Analyst Perspective

The global orthobiologics market is undergoing significant growth, driven by demographic changes, advancements in technology, and rising clinical demand for regenerative orthopedic treatments. As populations age particularly in developed regions, the prevalence of conditions such as osteoarthritis, spinal issues, and joint degeneration is increasing, leading to greater reliance on biologically based orthopedic solutions.

Orthobiologics Market Report Scope

Global Orthobiologics Market Report Segmentation

This report forecasts revenue and volume growth at the global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the orthobiologics market report based on product, application, end use, and region:

• Product Outlook (Revenue USD Million, 2021 - 2033)

  • Demineralized Bone Matrix (DBM)

  • Allograft

  • Bone Morphogenetic Protein (BMP)

  • Viscosupplementation

  • Synthetic Bone Substitutes

  • Stem Cell Therapy

• Application Outlook (Revenue USD Million, 2021 - 2033)

  • Spinal Fusion

  • Trauma Repair

  • Reconstructive Surgery

• End Use Outlook (Revenue USD Million, 2021 - 2033)

  • Hospitals

  • Orthopedic Clinics

• Regional Outlook Revenue USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • Spain

    • Italy

    • France

    • Denmark

    • Norway

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait